Top

Journal of Diabetes & Metabolic Disorders

05-05-2024 | Acute Pancreatitis | Review article

The effect of incretin-based drugs on the riks of acute pancreatitis: a review

Authors: Agata Czaplicka, Beata Kaleta

Published in: Journal of Diabetes & Metabolic Disorders

Abstract

Objectives

In recent years, new hypoglycaemic drugs that affect the incretin system have become increasingly popular in the treatment of type 2 diabetes mellitus (T2DM): glucagon-like receptor 1 agonists (GLP1RAs), dipeptidyl peptidase 4 inhibitors (DPP4is) and the recently developed dual glucagon-like receptor 1 agonist and glucose-dependent insulinotropic polypeptide (tirzepatide). Their main role of these drugs is to normalise blood glucose levels. In addition, GLP1RAs are approved for the treatment of excessive body weight. The efficacy of drugs affecting the incretin system is well described in the literature, however, there are still only few reports about their safety. This review aims to summarize the results of current research and meta-analyses on risk of acute pancreatitis (AP) during incretin-affecting drugs treatment.

Methods

A narrative review was performed using present literature in an attempt to identify the relationship between AP and incretin-affecting drugs. The following keywords were used: acute pancreatitis, glucagon-like receptor 1 agonists, dipeptidyl peptidase 4 inhibitors and tirzepatide.

Results

It was demonstrated that the use of DPP4is is safe for the majority of patients with T2DM, whereas a risk of AP should be noted in case of GLP1RAs therapy. To date, most studies found no significant association between tirzepatide therapy and the increased risk of AP.

Conclusion

The majority of studies have shown that DPP4is, GLP1RAs and tirzepatide are effective and safe in most T2DM patients. However, the follow-up time for patients treated with tirzepatide is short, therefore more studies are required to confirm the safety of this drug.

Wang YW, Lin JH, Yang CS. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Med (Baltim). 2022;101(34):e30072. https://doi.org/10.1097/MD.0000000000030072.CrossRef

Vázquez LA, Romera I, Rubio-de Santos M, Escalada J. Glycaemic Control and Weight reduction: a narrative review of New therapies for type 2 diabetes. Diabetes Ther. 2023;14(11):1771–84. https://doi.org/10.1007/s13300-023-01467-5.CrossRefPubMedPubMedCentral

Chobot A, Górowska-Kowolik K, Sokołowska M, Jarosz-Chobot P. Obesity and diabetes-not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7):e3042. https://doi.org/10.1002/dmrr.3042.CrossRefPubMedPubMedCentral

American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20–42. https://doi.org/10.2337/dc24-S002.CrossRef

American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78. https://doi.org/10.2337/dc24-S009.CrossRef

Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(13):1506–31. https://doi.org/10.1016/j.jacc.2018.08.1037.CrossRefPubMed

Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010. https://doi.org/10.1155/2015/697010.CrossRefPubMedPubMedCentral

Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X, et al. The weight-loss effect of GLP-1RAs glucagon-like Peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with Meta-Analysis and Trial Sequential Analysis of Randomized controlled trials. Am J Clin Nutr. 2023;118(3):614–26. https://doi.org/10.1016/j.ajcnut.2023.04.017.CrossRefPubMed

Roussey B, Calame P, Revel L, Zver T, Konan A, Piton G, et al. Liver spontaneous hypoattenuation on CT is an imaging biomarker of the severity of acute pancreatitis. Diagn Interv Imaging. 2022;103(9):401–7. https://doi.org/10.1016/j.diii.2022.03.008.CrossRefPubMed

10.

Kinoshita H, Zhang J, Ponthisarn A, Sharma M, Binh N, Siam A, et al. Clinical practice guidelines in the diagnosis and management of acute pancreatitis. Med Studies/Studia Medyczne. 2019;35(4):304–11. https://doi.org/10.5114/ms.2019.91248.CrossRef

11.

Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11. https://doi.org/10.1136/gutjnl-2012-302779.CrossRefPubMed

12.

Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C. et al Acute Pancreatitis: Diagnosis Treat Drugs. 2022;82(12):1251–76. https://doi.org/10.1007/s40265-022-01766-4.CrossRef

13.

Goodarzi MO, Petrov MS. Diabetes of the exocrine pancreas: implications for Pharmacological Management. Drugs. 2023;83(12):1077–90. https://doi.org/10.1007/s40265-023-01913-5.CrossRefPubMedPubMedCentral

14.

Boer GA, Holst JJ. Incretin Hormones and type 2 diabetes-mechanistic insights and therapeutic approaches. Biology (Basel). 2020;9(12):473. https://doi.org/10.3390/biology9120473.CrossRefPubMed

15.

Gumieniczek A, Berecka-Rycerz A. Metabolism and chemical degradation of New Antidiabetic drugs: a review of Analytical approaches for Analysis of Glutides and Gliflozins. Biomedicines. 2023;11(8):2127. https://doi.org/10.3390/biomedicines11082127.CrossRefPubMedPubMedCentral

16.

Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1–2):8–23. https://doi.org/10.1111/j.2040-1124.2010.00022.x.CrossRefPubMedPubMedCentral

17.

Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Horm (Athens). 2018;17(3):333–50. https://doi.org/10.1007/s42000-018-0038-0.CrossRef

18.

Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a Comprehensive Review of Randomised controlled trials. Int J Mol Sci. 2023;24(13):10449. https://doi.org/10.3390/ijms241310449.CrossRefPubMedPubMedCentral

19.

Cesaro A, De Michele G, Fimiani F, Acerbo V, Scherillo G, Signore G, et al. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options. Front Cardiovasc Med. 2023;10:1187735. https://doi.org/10.3389/fcvm.2023.1187735.CrossRefPubMedPubMedCentral

20.

Shi FH, Li H, Cui M, Zhang ZL, Gu ZC, Liu XY. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and Meta-analysis of Randomized controlled trials. Front Pharmacol. 2018;9:576. https://doi.org/10.3389/fphar.2018.00576.CrossRefPubMedPubMedCentral

21.

Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS ONE. 2023;18(8):e0289616. https://doi.org/10.1371/journal.pone.0289616.CrossRefPubMedPubMedCentral

22.

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.CrossRefPubMed

23.

Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. https://doi.org/10.3389/fendo.2022.1043789.CrossRefPubMed

24.

El-Arabey AA, Zhang H, Abdalla M, Al-Shouli ST, Alkhalil SS, Liu Y. Metformin as a promising target for DPP4 expression: computational modeling and experimental validation. Med Oncol. 2023;40(10):277. https://doi.org/10.1007/s12032-023-02140-4.CrossRefPubMedPubMedCentral

25.

Chen SY, Kong XQ, Zhang KF, Luo S, Wang F, Zhang JJ. DPP4 as a potential candidate in Cardiovascular Disease. J Inflamm Res. 2022;15:5457–69. https://doi.org/10.2147/JIR.S380285.CrossRefPubMedPubMedCentral

26.

Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642–53. https://doi.org/10.1038/s41574-020-0399-8.CrossRefPubMed

27.

Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015;6:386. https://doi.org/10.3389/fimmu.2015.0038.CrossRefPubMedPubMedCentral

28.

Bernardini F, Nusca A, Coletti F, La Porta Y, Piscione M, Vespasiano F, et al. Incretins-based therapies and their Cardiovascular effects: New Game-Changers for the management of patients with diabetes and Cardiovascular Disease. Pharmaceutics. 2023;15(7):1858. https://doi.org/10.3390/pharmaceutics15071858.CrossRefPubMedPubMedCentral

29.

Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, et al. Re-adjudication of the Trial evaluating Cardiovascular outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clin Cardiol. 2022;45(7):794–801. https://doi.org/10.1002/clc.23844.CrossRefPubMedPubMedCentral

30.

Seino Y, Kaku K, Kadowaki T, Okamoto T, Sato A, Shirakawa M, et al. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes Obes Metab. 2021;23(6):1342–50. https://doi.org/10.1111/dom.14346.CrossRefPubMedPubMedCentral

31.

Li J, He K, Ge J, Li C, Jing Z. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;172:108656. https://doi.org/10.1016/j.diabres.2021.108656.CrossRefPubMed

32.

Tseng CM, Liao WC, Chang CY, Lee CT, Tseng CH, Hsu YC, et al. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: a population-based study in Taiwan. Pancreatology. 2017;17(1):76–82. https://doi.org/10.1016/j.pan.2016.10.003.CrossRefPubMed

33.

Storgaard H, Cold F, Gluud LL, Vilsbøll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):906–8. https://doi.org/10.1111/dom.12885.CrossRefPubMed

34.

Singh AK, Gangopadhyay KK, Singh R. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Rev Clin Pharmacol. 2020;13(4):461–8. https://doi.org/10.1080/17512433.2020.1736041.CrossRefPubMed

35.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183.CrossRefPubMed

36.

Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. https://doi.org/10.3389/fpubh.2022.996179.CrossRefPubMedPubMedCentral

37.

Aroda VR, Erhan U, Jelnes P, Meier JJ, Abildlund MT, Pratley R, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023;25(5):1385–97. https://doi.org/10.1111/dom.14990.CrossRefPubMed

38.

Javed H, Kogilathota Jagirdhar GS, Kashyap R, Vekaria PH. Liraglutide-Induced Pancreatitis: a Case Report and Literature Review. Cureus. 2023;15(4):e38263. https://doi.org/10.7759/cureus.38263.CrossRefPubMedPubMedCentral

39.

Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015;38(6):1058–66. https://doi.org/10.2337/dc13-1210.CrossRefPubMed

40.

Caparrotta TM, Templeton JB, Clay TA, Wild SH, Reynolds RM, Webb DJ, et al. Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in type 2 diabetes: a systematic review of Population-based Observational studies. Diabetes Ther. 2021;12(4):969–89. https://doi.org/10.1007/s13300-021-01021-1.CrossRefPubMedPubMedCentral

41.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149–58. https://doi.org/10.2337/dc13-2761.CrossRefPubMedPubMedCentral

42.

Chin R, Nagaoka S, Nakasawa H, Tanaka Y, Inagaki N. Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study. J Diabetes Investig. 2023;14(2):247–58. https://doi.org/10.1111/jdi.13932.CrossRefPubMed

43.

Al-Kawas F, Anderson MA, Enns R, Wilson TH, Johnson S, Mallory JM, PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE. Endocr Pract. 2019;25(7):698–716. https://doi.org/10.4158/EP-2018-0507.CrossRefPubMed

44.

Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.CrossRefPubMed

45.

Shahbazi M, Qudsiya Z, Fahel A, Amini A, Tanoli T. First reported case of Dulaglutide-Induced Acute Pancreatitis with normal serum lipase level. Cureus. 2023;15(6):e40576. https://doi.org/10.7759/cureus.40576.CrossRefPubMedPubMedCentral

46.

Khan AB, Shah A, Ahmad S, Khan MI, Amir A. Dulaglutide (Trulicity)-Induced Acute Pancreatitis: a Case Report. Cureus. 2023;15(5):e38630. https://doi.org/10.7759/cureus.38630.CrossRefPubMedPubMedCentral

47.

AlSaadoun AR, AlSaadoun TR, Al Ghumlas AK. Liraglutide Overdose-Induced Acute Pancreatitis. Cureus. 2022;14(1):e21616. https://doi.org/10.7759/cureus.21616.CrossRefPubMedPubMedCentral

48.

Dolan RD, Bazarbashi AN, Lo A, Smith BN. Liraglutide-Induced Hemorrhagic Pancreatitis in a nondiabetic patient. ACG Case Rep J. 2020;7(5):e00380. https://doi.org/10.14309/crj.0000000000000380.CrossRefPubMedPubMedCentral

49.

Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE, et al. 2 DIABETES MANAGEMENT ALGORITHM– 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020;26(1):107–39. https://doi.org/10.4158/CS-2019-0472.CrossRefPubMed

50.

Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, Murorani K, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17(4):430–4. https://doi.org/10.1111/dom.12381.CrossRefPubMed

51.

Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al. Association between Incretin-based drugs and the risk of Acute Pancreatitis. JAMA Intern Med. 2016;176(10):1464–73. https://doi.org/10.1001/jamainternmed.2016.1522.CrossRefPubMed

52.

Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, et al. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Res Care. 2021;9(1):e001787. https://doi.org/10.1136/bmjdrc-2020-001787.CrossRefPubMedPubMedCentral

53.

Lee M, Sun J, Han M, Cho Y, Lee JY, Nam CM, et al. Nationwide trends in Pancreatitis and Pancreatic Cancer Risk among patients with newly diagnosed type 2 diabetes receiving Dipeptidyl Peptidase 4 inhibitors. Diabetes Care. 2019;42(11):2057–64. https://doi.org/10.2337/dc18-2195.CrossRefPubMed

54.

Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of Acute Pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40(2):284–6. https://doi.org/10.2337/dc15-1707.CrossRefPubMed

55.

Sayiner ZA, Inan Demiroğlu G, Akarsu E, Araz M. The relationship between Dipeptidyl Peptidase-4 inhibitor usage and Asymptomatic Amylase Lipase Increment in type 2 diabetes Mellitus patients. Turk J Pharm Sci. 2020;17(1):68–73. https://doi.org/10.4274/tjps.galenos.2018.83788.CrossRefPubMedPubMedCentral

56.

Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on Glycemic Control in patients with type 2 diabetes: the SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534–45. https://doi.org/10.1001/jama.2022.0078.CrossRefPubMedPubMedCentral

57.

Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251–61. https://doi.org/10.1007/s00125-022-05715-4.CrossRefPubMedPubMedCentral

58.

Xie Z, Hu J, Gu H, Li M, Chen J. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. Front Endocrinol (Lausanne). 2023;14:1244432. https://doi.org/10.3389/fendo.2023.1244432.CrossRefPubMed

59.

Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, et al. Adverse events related to Tirzepatide. J Endocr Soc. 2023;7(4):bvad016. https://doi.org/10.1210/jendso/bvad016.CrossRefPubMedPubMedCentral

60.

Tang Y, Zhang L, Zeng Y, Wang X, Zhang M. Efficacy and safety of tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1016639. https://doi.org/10.3389/fphar.2022.1016639.CrossRefPubMedPubMedCentral

61.

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide once Weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15. https://doi.org/10.1056/NEJMoa2107519.CrossRefPubMed

Title: The effect of incretin-based drugs on the riks of acute pancreatitis: a review
Authors: Agata Czaplicka
Beata Kaleta
Publication date: 05-05-2024
Publisher: Springer International Publishing
Keywords: Acute Pancreatitis
Tirzepatide
Semaglutide
Liraglutide
Dulaglutid
Published in: Journal of Diabetes & Metabolic Disorders
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-024-01430-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com